MetLife (MET) Valuation Check After Mixed Recent Share Price Performance

MetLife stock overview after recent performance

MetLife (MET) shares have seen mixed recent performance, with a small daily gain alongside a stronger week and month, but a negative move over the past 3 months and year to date.

See our latest analysis for MetLife.

MetLife’s 7 day share price return of 5.56% and 30 day share price return of 5.74% contrast with a 7.06% year to date share price decline. However, the 1 year total shareholder return of 8.10% and 3 year total shareholder return of 37.02% point to a stronger longer term track record.

If you are assessing insurers like MetLife and want to see what else is moving, this is a good moment to scan 19 top founder-led companies

With MetLife trading at $74.65 and sitting at a discount to analyst price targets and one valuation estimate, the key question is whether this gap signals an undervalued insurer or if the market already reflects potential future growth.

Most Popular Narrative: 18% Undervalued

MetLife’s most followed narrative places fair value at $90.50 per share, comfortably above the recent $74.65 close, and links that difference to long term expansion and business mix changes.

Strong, sustained premium and sales growth in high-potential international markets (Asia, Latin America, EMEA) is described as positioning MetLife to capture growing middle-class wealth and increased insurance penetration, which in turn is cited as supporting long-term revenue and top-line growth.

Strategic expansion of asset-light, fee-generating businesses (such as employee benefits, asset management, and longevity reinsurance), combined with disciplined capital management, is described as supporting higher return on equity and more consistent, less capital-intensive earnings growth.

Read the complete narrative.

Want to see what is driving that valuation gap? The narrative emphasizes steadier fees, a shifting profit mix, and a specific path for margins and earnings over the next few years.

Result: Fair Value of $90.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on investment and underwriting conditions improving; credit losses or reserve surprises on legacy blocks could quickly challenge the 18% undervalued narrative.

Find out about the key risks to this MetLife narrative.

Another View: What The P/E Says

The narrative and DCF style work suggest upside, but the simple P/E check is more cautious. At a 15.3x P/E, MetLife trades above the US Insurance industry at 11.5x, above peers at 14.8x, and above its own fair ratio of 14.4x, which points to valuation risk rather than clear-cut value. So is the discount to fair value a genuine opportunity, or just compensation for these higher multiples?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value, risks, and rewards, now is a good time to review the underlying data yourself and decide how comfortable you are with the trade off described in 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one insurer, you miss out on other potential opportunities. Use the screeners below to pressure test and enrich your broader watchlist.

• Target resilient names by focusing on 73 resilient stocks with low risk scores. These aim to keep volatility in check while still offering meaningful exposure to equities.
• Zero in on quality at a reasonable price by scanning 62 high quality undervalued stocks, which pair solid fundamentals with more modest valuation signals.
• Build a shortlist of income candidates using the 11 dividend fortresses. These highlight companies combining higher yields with a focus on stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com